National Cancer Institute; Notice of Closed Meetings, 56622 [2017-25732]
Download as PDF
56622
Federal Register / Vol. 82, No. 228 / Wednesday, November 29, 2017 / Notices
pmangrum on DSK3GDR082PROD with NOTICES1
concatenated L2 peptides for the
prevention of Human Papillomavirus
(HPV) infection and associated diseases.
Specifically excluded from the field of
use are L2 based virus-like particles
(VLPs), L1/L2 chimeric peptides, and
L1/L2 chimeric peptide/protein based
VLPs.’’
The subject technologies are
papillomavirus L2 capsid protein based
vaccines against HPV. The L2 protein is
the minor papillomavirus capsid protein
for papillomaviruses. It is known that
antibodies to this protein can neutralize
homologous infection. Furthermore, L2
proteins can induce cross-neutralizing
antibodies. Specifically, epitopes at the
N-terminus of L2 shared by cutaneous
and mucosal types of papillomavirus
types and by types that infect divergent
species are broadly cross-neutralizing.
These epitopes at the N-terminus of L2
can be used to elicit cross-neutralizing
antibodies against different types of
HPV.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: November 14, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–25744 Filed 11–28–17; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
15:19 Nov 28, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI SPORE
V Review.
Date: February 5–6, 2018.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Washingtonian
Marriott, 9751 Washingtonian Boulevard,
Gaithersburg, MD 20878.
Contact Person: Mukesh Kumar, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W618,
Bethesda, MD 20892–9750, 240–276–6611,
mukesh.kumar3@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Molecular
and Cellular Analysis Technologies.
Date: February 8, 2018.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Nadeem Khan, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W260, Bethesda, MD 20892–
9750, 240–276–5856, nadeem.khan@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI SPORE
VI Review.
Date: February 8–9, 2018.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Washingtonian
Marriott, 9751 Washingtonian Boulevard,
Gaithersburg, MD 20878.
Contact Person: Anita T. Tandle, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W248,
Bethesda, MD 20892–9750, 240–276–5007,
tandlea@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Quantitative Imaging.
Date: February 14, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
4W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Eduardo E. Chufan, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W254, Bethesda, MD 20892–
9750, 240–276–7975, chufanee@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 22, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–25732 Filed 11–28–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: T-Cells Transduced with HLA
A11 Restricted CT–RCC HERV–E
Reactive T-Cell Receptors for the
Treatment of Renal Cell Carcinoma
National Institutes of Health.
Notice.
AGENCY:
ACTION:
The National Heart, Lung, and
Blood Institute (‘‘NHLBI’’), an institute
of the National Institutes of Health; an
agency within the Department of Health
and Human Services, is contemplating
the grant of an Exclusive Patent License
to commercialize the invention(s)
embodied in the intellectual property
estate stated in the Summary
Information section of this notice to
T-Cure Bioscience, Inc. located in
Thousand Oaks, California and
incorporated under the laws of
Delaware.
DATES: Only written comments and/or
applications for a license which are
received by the NHLBI Office of
Technology Transfer and Development
SUMMARY:
E:\FR\FM\29NON1.SGM
29NON1
Agencies
[Federal Register Volume 82, Number 228 (Wednesday, November 29, 2017)]
[Notices]
[Page 56622]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25732]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI SPORE V Review.
Date: February 5-6, 2018.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Gaithersburg Washingtonian Marriott, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Mukesh Kumar, Ph.D., Scientific Review Officer,
Research Program Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W618, Bethesda, MD 20892-9750, 240-276-6611, mukesh.kumar3@nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Molecular and Cellular Analysis Technologies.
Date: February 8, 2018.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute, Shady Grove, 9609 Medical
Center Drive, Room 7W030, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Nadeem Khan, Ph.D., Scientific Review Officer,
Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W260, Bethesda, MD 20892-9750, 240-276-5856,
nadeem.khan@nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI SPORE VI Review.
Date: February 8-9, 2018.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Gaithersburg Washingtonian Marriott, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Anita T. Tandle, Ph.D., Scientific Review
Officer, Research Program Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W248, Bethesda, MD 20892-9750, 240-276-5007,
tandlea@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Quantitative Imaging.
Date: February 14, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute, Shady Grove, 9609 Medical
Center Drive, Room 4W030, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Eduardo E. Chufan, Ph.D., Scientific Review
Officer, Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W254, Bethesda, MD 20892-9750, 240-276-7975,
chufanee@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: November 22, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-25732 Filed 11-28-17; 8:45 am]
BILLING CODE 4140-01-P